Kangstem Biotech Co. Ltd (217730) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Kangstem Biotech Co. Ltd KRW 327, price KRW 2,240, upside -85.4%, quality 22 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Kangstem Biotech Co. Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
Kangstem Biotech Co., Ltd. a biopharmaceutical company, develops stem cell therapeutic products for rare and incurable diseases. The company's stem cell therapy products include Furestem-AD for treatment of subacute and chronic atopic dermatitis; Furestem-RA to treat rheumatoid arthritis; and Furestem-CD for treatment of active crohn's disease.
Show more
Kangstem Biotech Co., Ltd. a biopharmaceutical company, develops stem cell therapeutic products for rare and incurable diseases. The company's stem cell therapy products include Furestem-AD for treatment of subacute and chronic atopic dermatitis; Furestem-RA to treat rheumatoid arthritis; and Furestem-CD for treatment of active crohn's disease. It also provides stem cell conditioned media, such as umbilical cord blood-derived stem cell conditioned media that includes epidermal, vascular endothelium, keratinocyte, hepatocyte, transforming, and platelet-derived growth factors, as well as growth and differentiation factor 11, and Fibroblast growth factor 2 for skin growth and regeneration. In addition, the company offers stem cell culture media, including KSB-3 kit, a medium for culturing the human mesenchymal stem cell; and cell freezing and thawing platform. Further, it provides pharmaceutical contract manufacturing and development services. Kangstem Biotech Co., Ltd. was founded in 2010 and is headquartered in Seoul, South Korea.
Stock analysis
Kangstem Biotech Co. Ltd (217730) currently trades at 2,240 KRW, while our model-based Fair Value estimate is 327.32 KRW, 85.4% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 94/100, which puts the evidence level at low.
Scenario range: 216.03 KRW (bear) to 409.15 KRW (bull), the price of 2,240 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 22/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Kangstem Biotech Co. Ltd reported revenue of 3.6B KRW in FY2025 versus 12.4B KRW in FY2021, a compound −26.7%/yr. Reported net income was −10.5B KRW in FY2025.
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (medium confidence).
What moves the price
The share trades about 51% below its 52-week high and 60% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −85%, 217730 screens richer than that median.
Fair Value models
Bear 216.03 KRWFair Value 327.32 KRWBull 409.15 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−53.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−39.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−17.1%
Start year 2020 (pandemic). Over 10 years: +9.2% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.2%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−218.1% (2020) → −494.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Kangstem Biotech Co. Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 576 stocks
Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score26 · Bottom 25%
Fair Value upside−85.4% · Bottom 25%
Profitability
Return on assets−17.6% · Below median
Growth and dividend
Revenue growth−15.6% · Bottom 25%
Balance sheet
Debt / equity0.03× · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/S (TTM)0.11× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)98· sector 97
DIVIDEND (yield)0· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Kangstem Biotech Co. Ltd (217730) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 327.32 KRW versus a price of 2,240 KRW, about −85% upside (overvalued).
What is the fair value of 217730?
Our model-based fair value for Kangstem Biotech Co. Ltd is 327.32 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 2,240 KRW.
What is the quality score of 217730?
Kangstem Biotech Co. Ltd has a Quality Score of 22/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Kangstem Biotech Co. Ltd (217730)?
Our model-based price target is the fair value of 327.32 KRW (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 216.03 KRW, optimistic scenario 409.15 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Kangstem Biotech Co. Ltd stock forecast for 2026?
Our models put fair value at 327.32 KRW, about −85% upside versus a price of 2,240 KRW (overvalued). Cautious scenario 216.03 KRW, optimistic scenario 409.15 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Kangstem Biotech Co. Ltd (217730)?
Kangstem Biotech Co. Ltd reported trailing-twelve-month revenue of about 1.5B KRW (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Kangstem Biotech Co. Ltd (217730)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Kangstem Biotech Co. Ltd it is 327.32 KRW per share (as of Sep 24, 2026), against a price of 2,240 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Kangstem Biotech Co. Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 217730 trades above its calculated fair value: price 2,240 KRW, fair value 327.32 KRW, a gap of about −85% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 217730?
No. The price is what the market pays today (2,240 KRW); the fair value is what the company's own numbers justify (327.32 KRW). For Kangstem Biotech Co. Ltd the two are 1,913 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Kangstem Biotech Co. Ltd worth?
The market values Kangstem Biotech Co. Ltd at about 211B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 2,240 KRW; our models calculate a fair value of 327.32 KRW per share.
What do the bullish and bearish scenarios say about 217730?
Our models span a range for Kangstem Biotech Co. Ltd: cautious scenario 216.03 KRW, base 327.32 KRW, optimistic 409.15 KRW per share (as of Sep 24, 2026, price 2,240 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Kangstem Biotech Co. Ltd (217730)?
Balance-sheet figures for Kangstem Biotech Co. Ltd (as of Sep 24, 2026): return on equity −47.9%, debt of 0.03 per unit of equity. They feed the Quality Score of 22/100, which measures business quality independently of the share price.
How far is 217730 from its 52-week high?
Kangstem Biotech Co. Ltd trades at 2,240 KRW, about 51% below its 52-week high of 4,615 KRW and 60% above the low of 1,397 KRW (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of 327.32 KRW is for.
Which stocks are comparable to Kangstem Biotech Co. Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Kangstem Biotech Co. Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 2,240 KRW, calculated fair value 327.32 KRW (−85%), Quality Score 22/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 217730 calculated?
We run Kangstem Biotech Co. Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 327.32 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Kangstem Biotech Co. Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Kangstem Biotech Co. Ltd (217730)?
The closing price on Oct 2, 2026 was 2,240 KRW. Our model-based fair value is 327.32 KRW, about −85% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Kangstem Biotech Co. Ltd right now?
The price sits above even our optimistic bull case (409.15 KRW). The favourable scenario is already priced in. Weak quality (22/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (216.03 KRW to 409.15 KRW) leaves room in how you read the outcome.
Key figures of Kangstem Biotech Co. Ltd
How large is the market capitalisation of Kangstem Biotech Co. Ltd (217730)?
The market capitalisation of Kangstem Biotech Co. Ltd is 211B KRW (≈ $157M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the return on equity of Kangstem Biotech Co. Ltd (217730)?
The return on equity (ROE) of Kangstem Biotech Co. Ltd is −47.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Kangstem Biotech Co. Ltd (217730)?
On an EBIT basis the return on assets of Kangstem Biotech Co. Ltd is −23.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Kangstem Biotech Co. Ltd (217730)?
The operating margin of Kangstem Biotech Co. Ltd is −568% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Kangstem Biotech Co. Ltd (217730)?
Revenue at Kangstem Biotech Co. Ltd is growing −15.6% versus a year earlier (3y avg −39.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Kangstem Biotech Co. Ltd (217730) generate?
The free cash flow of Kangstem Biotech Co. Ltd is −12.3B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Kangstem Biotech Co. Ltd (217730) carry?
The net debt of Kangstem Biotech Co. Ltd is 5.8B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Kangstem Biotech Co. Ltd in the live analysis
One click puts Kangstem Biotech Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
